Table 4.
Multivariate analysis for evaluating the risk of sepsis in the validation cohort based on the PCT/HLA-DRA ratio or Procalcitonin levels.
| Multivariate analysis for PCT/HLA-DRA ratio | Multivariate analysis for PCT | |||||||
|---|---|---|---|---|---|---|---|---|
| OR | [CI 95%] | p | OR | [CI 95%] | p | |||
| SOFA score | 0.94 | 0.71 | 1.25 | 0.690 | 1.00 | 0.77 | 1.30 | 0.992 |
| Cancer | 0.17 | 0.02 | 1.34 | 0.092 | 0.20 | 0.03 | 1.34 | 0.097 |
| Urgent Surgery | 45.68 | 2.80 | 744.81 | 0.007 | 31.87 | 2.95 | 344.67 | 0.004 |
| Neutrophil concentration in blood (cells/mm3) | 1.00 | 1.00 | 1.00 | 0.471 | 1.00 | 1.00 | 1.00 | 0.754 |
| C Reactive Protein | 1.00 | 0.98 | 1.02 | 0.941 | 1.01 | 0.99 | 1.02 | 0.503 |
| PCT/HLA-DRA > OOP (0.0003) | 34.86 | 1.22 | 995.08 | 0.038 | — | — | — | — |
| PCT > OOP (1.115 ng/mL) | — | — | — | — | 5.52 | 0.40 | 75.78 | 0.201 |
Optimal operating points (OOP) obtained in the derivation cohort were tested in the validation cohort.